Literature DB >> 11038215

Familial papillary thyroid carcinoma: genetics, criteria for diagnosis, clinical features, and surgical treatment.

T J Musholt1, P B Musholt, T Petrich, G Oetting, W H Knapp, J Klempnauer.   

Abstract

Hereditable predisposition to papillary thyroid carcinoma (PTC) and multinodular goiter (MNG) without evidence of an association with other malignancies as a distinct entity was recognized only recently. A meta-review of the literature on familial PTC (FPTC) was undertaken, and characteristics of families with frequent occurrence of PTC or MNG (or both) were summarized. A database on thyroid cancer patients maintained in our institution was searched for potential FPTC families. Clinical examinations were performed in 6 of 12 Hannover kindreds identified, and blood samples of all family members were collected for genetic analyses. Clinical presentations and histopathologic features of the FPTC cases were compiled. Based on the FPTC meta-review and own experience, predictive criteria to identify families at risk were developed: Exclusion criteria were previous radiation exposure and coincidence with neoplasia syndromes. Primary criteria for susceptibility to FPTC are (1) PTC in two or more first-degree relatives and (2) MNG in at least three first- or second-degree relatives of a PTC patient. Secondary criteria are diagnosis in a patient younger than 33 years, multifocal or bilateral PTC, organ-exceeding tumor growth (T4), metastasis (N1, M1), and familial accumulation of adolescent-onset thyroid disease. A hereditary predisposition to PTC is considered if both primary criteria or one primary criterion plus three secondary criteria are present. Family history-taking is recommended for all PTC patients to identify FPTC kindreds at risk. Blood relatives of FPTC index patients who harbor MNG should undergo thorough and regular clinical screening. Suspicious lesions should prompt early surgical intervention.

Entities:  

Mesh:

Year:  2000        PMID: 11038215     DOI: 10.1007/s002680010233

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  23 in total

1.  Evidence for interaction between the TCO and NMTC1 loci in familial non-medullary thyroid cancer.

Authors:  J D McKay; D Thompson; F Lesueur; K Stankov; A Pastore; C Watfah; S Strolz; G Riccabona; R Moncayo; G Romeo; D E Goldgar
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

Review 2.  An update on familial nonmedullary thyroid cancer.

Authors:  Sabrine A Ammar; Wilson M Alobuia; Electron Kebebew
Journal:  Endocrine       Date:  2020-03-11       Impact factor: 3.633

3.  Familial Papillary Thyroid Carcinoma (FPTC): a Retrospective Analysis in a Sample of the Bulgarian Population for a 10-Year Period.

Authors:  Kalin Vidinov; Dragomira Nikolova
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

4.  Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).

Authors:  Joana S Pereira; Joana Gomes da Silva; Rute Alexandra Tomaz; António Evaristo Pinto; Maria João Bugalho; Valeriano Leite; Branca Maria Cavaco
Journal:  Endocrine       Date:  2014-11-09       Impact factor: 3.633

Review 5.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

Review 6.  German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors.

Authors:  Henning Dralle; Thomas J Musholt; Jochen Schabram; Thomas Steinmüller; Andreja Frilling; Dietmar Simon; Peter E Goretzki; Bruno Niederle; Christian Scheuba; Thomas Clerici; Michael Hermann; Jochen Kußmann; Kerstin Lorenz; Christoph Nies; Peter Schabram; Arnold Trupka; Andreas Zielke; Wolfram Karges; Markus Luster; Kurt W Schmid; Dirk Vordermark; Hans-Joachim Schmoll; Reinhard Mühlenberg; Otmar Schober; Harald Rimmele; Andreas Machens
Journal:  Langenbecks Arch Surg       Date:  2013-03-03       Impact factor: 3.445

Review 7.  The impact of family history on non-medullary thyroid cancer.

Authors:  I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito
Journal:  Eur J Surg Oncol       Date:  2016-08-11       Impact factor: 4.424

8.  Loss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinoma.

Authors:  Hugo João Prazeres; Fernando Rodrigues; Paula Soares; Plamen Naidenov; Paulo Figueiredo; Beatriz Campos; Manuela Lacerda; Teresa C Martins
Journal:  Fam Cancer       Date:  2007-09-07       Impact factor: 2.375

9.  Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma.

Authors:  M Hidalgo; M E Saez; F J Martinez-Tello; F J Moron; E Ferrero-Herrero; M Labalde-Martinez; D Rigopoulou; C Ballestin-Carcavilla; A Ruiz; J L Royo; R Ramirez-Lorca
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

Review 10.  Familial non-medullary thyroid carcinoma: an update.

Authors:  Vânia Nosé
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.